S&P Futures
4,129.50 +6.00 (+0.15%) Dow Futures
33,941.00 +7.00 (+0.02%) Nasdaq Futures
12,552.00 +36.50 (+0.29%) Russell 2000 Futures
1,966.50 +1.40 (+0.07%) Crude Oil
75.85 +1.74 (+2.35%) Gold
1,885.50 +6.00 (+0.32%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.2700 |
| Open | 4.2600 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 800 |
| Day's Range | 4.1400 - 4.3800 |
| 52 Week Range | 2.0100 - 12.1500 |
| Volume | |
| Avg. Volume | 720,325 |
| Market Cap | 195.915M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8450 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BCAB
Related Research
- BioAtla, Inc.Daily – Vickers Top Buyers & Sellers for 06/10/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat8 months agoArgus Research
- Simply Wall St.
Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year
If you want to know who really controls BioAtla, Inc. ( NASDAQ:BCAB ), then you'll have to look at the makeup of its...
- GlobeNewswire
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is being initiated; anticipate first patient dosed this quarter BA3071 Phase 1 study ongoing with first two dose escalation cohorts completed; third cohort (70mg) on-going CAB clinical programs continue
- PR Newswire
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid.
